Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide,

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims & Hers stock plunged more than 50% at one point. Is this once-high-flying healthcare stock a smart buy now?

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core

Hims & Hers Health's HIMS short percent of float has risen 5.58% since its last report. The company recently reported that it has 54.73 million shares sold short, which is 28.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average.